Key result
Cibenzoline significantly reduced the left ventricular pressure gradient from 79 mmHg to 24 mmHg at 2 hours and 20 mmHg at 3 months in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Why the study?
Does cibenzoline reduce left ventricular pressure gradient and improve diastolic function in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction?
Does cibenzoline reduce left ventricular pressure gradient and improve diastolic function in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction?
Cibenzoline significantly reduces left ventricular pressure gradient and improves diastolic function in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Answers are grounded in this paper and cite their sources.
May support gradient relief in midventricular HOCM; leaves open randomized confirmation before practice change.
BACKGROUND: Recent interventional and surgical therapies to attenuate left ventricular pressure gradient (LVPG) can be difficult to perform in patients with hypertrophic obstructive cardiomyopathy (HOCM) caused by midventricular obstruction (MVO), owing to the risk of inducing or deteriorating mitral regurgitation. METHODS AND RESULTS: The effects of the antiarrhythmic drug, cibenzoline, on LVPG and left ventricular (LV) diastolic function estimated by the change in the transmitral Doppler flow pattern were examined in 23 patients with HOCM and MVO. Hemodynamic changes 2 h after a single dose of 200 mg of cibenzoline and 3 months after oral administration of 300-450 mg of cibenzoline per day were examined. At 2 h after the treatment, LVPG decreased from 79+/-37 mmHg to 24+/-21 mmHg (p < 0.0001). E-wave velocity significantly increased and A-wave velocity significantly decreased, and thus the E/A ratio increased from 0.83+/-0.39 to 1.36+/-0.50 (p < 0.0001). After 3 months of treatment, LVPG remained decreased, and the E-wave and A-wave velocities and the E/A ratio remained improved. CONCLUSIONS: Cibenzoline can attenuate LVPG and ameliorate LV diastolic dysfunction in patients with HOCM caused by MVO, which suggests a new strategy for the management of this condition.
No takes yet. Share an insight, caveat, or question.
Hamada et al. (2005) studied Hypertrophic obstructive cardiomyopathy caused by midventricular obstruction (n=23). Cibenzoline vs. Baseline was evaluated on Left ventricular pressure gradient (LVPG) at 2 hours (p=<0.0001). Cibenzoline significantly reduced the left ventricular pressure gradient from 79 mmHg to 24 mmHg at 2 hours and 20 mmHg at 3 months in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Synapse has enriched 10 related papers. Consider them for comparative context: